Dementia Across the Spectrum Webinar Series – Mild to Moderate Dementia

Dementia's Escalating Crisis

Dementia has surged into focus as populations age and new treatments emerge. In 2025, trials for GLP-1 agonists like semaglutide, repurposed from diabetes drugs, showed promise in slowing cognitive decline, building on anti-amyloid therapies approved two years prior. These developments follow a decade of intensified research, with 182 clinical trials underway globally, many targeting mild to moderate stages where intervention yields the most benefit. Yet, the pipeline's expansion highlights a recent pivot: from 2024's 138 novel drugs, emphasis now includes metabolic and repurposed agents, driven by failures in earlier amyloid-focused efforts.

The human toll is immense. Worldwide, 57 million people lived with dementia in 2021, a figure set to reach 152 million by 2050, with 71% in low- and middle-income countries ill-equipped for the surge. In the US alone, 7.2 million over-65s face it today, contributing to 120,122 deaths in 2022—making it the seventh-leading cause of death. Families shoulder much of the burden: 19.2 billion hours of unpaid care in 2024, valued at $413.5 billion, often leading to caregiver depression and lost wages totaling $8.2 billion annually.

Economic pressures compound the issue. Global costs hit $1.3 trillion in 2019, with US projections at $781 billion for 2025—$232 billion in direct medical and long-term care, plus $302 billion in quality-of-life losses for patients. By 2050, attributable spending could reach $1.6 trillion, representing 11% of health expenditures, potentially straining Medicare ($106 billion in 2025) and Medicaid ($58 billion). Risks of inaction are stark: without early detection, preventable hospitalizations rise, and links to air pollution or traumatic brain injuries—doubling dementia risk—go unaddressed.

Less visible are the policy frictions. In residential care, tensions arise between medical priorities, like anti-amyloid infusions requiring frequent monitoring, and social needs for interpersonal support. Safety measures, such as wheelchairs to prevent falls, can erode mobility, accelerating dependency. Cultural and racial biases in nursing homes add layers: reports of unchecked racism or sexism from residents with cognitive impairments create toxic environments, yet policies forbidding such behavior have succeeded in some facilities, proving change is possible but uneven.

Stakeholder conflicts deepen the challenge. Drug developers push for broader approvals amid 2025 trial readouts for candidates like AR1001 and remternetug, but payers balk at costs—leqembi infusions exceed $26,000 yearly. In low-income settings, eHealth interventions offer scalable support but face implementation hurdles, like funding gaps. Meanwhile, environmental factors, including PM2.5 pollution tied to higher dementia incidence, demand cross-sector action, pitting public health against industrial interests.